This document discusses immunotherapeutics and immunity. It defines immunity as the body's ability to protect itself from infectious disease. There are two main types of immunity: innate and adaptive. Immunotherapy involves stimulating, enhancing, suppressing, or desensitizing the immune system to treat or prevent disease like cancer or autoimmune disorders. The document outlines various immunotherapeutic approaches including immunostimulants, monoclonal antibodies, antibody-directed enzyme prodrug therapy, immunotoxins, and immunomodulators like adaptive cell therapy and cancer vaccines.
This slideshare conatins detailed overview of immunotheraphy,humanisation of antibodies and its clinical application
this is the topic from cellular and molecular pharmacology of m pharmacy first year
immunotheraphy is further classified to its various types which has been discussed individually
its also conatins various immunotheraphy drugs which has other clinical advantages
In this slideshare i have discussed about the digoxin, its property,different analytical methods of digoxin and the general procedure of immunoassay of digoxin.
Also additionally i have added 10 mcq related to the topic with multiple options and correct option as well.
This slideshare conatins detailed overview of immunotheraphy,humanisation of antibodies and its clinical application
this is the topic from cellular and molecular pharmacology of m pharmacy first year
immunotheraphy is further classified to its various types which has been discussed individually
its also conatins various immunotheraphy drugs which has other clinical advantages
In this slideshare i have discussed about the digoxin, its property,different analytical methods of digoxin and the general procedure of immunoassay of digoxin.
Also additionally i have added 10 mcq related to the topic with multiple options and correct option as well.
genetic variations and its role in health/ pharmacologysrivani mandaloju
Here is the reference for the above topic. I have collected the maximum information that i got from the internet. If any one need the complete information comment here.
Introduction to Screening Models of Anti-Atherosclerosis
Atherosclerosis, Screening models, In vitro models, In vivo models
Presented by
SHAIK FIRDOUS BANU
Department of Pharmacology
Introduction to Immunotherapeutics
Cell mediated & humoral immunity, Immunosuppressants, Immunostimulants
Presented by
G. Sai Swetha
Department of Pharmacology
Immunoassays have been widely used in many important areas of pharmaceutical analysis such as diagnosis of diseases, therapeutic drug monitoring, clinical pharmacokinetic and bioequivalence studies in drug discovery and pharmaceutical industries.
In this slide contains diabetics, classification, symptoms, complication, invivo and invitro screening models of anti diabetics.
Presented by: GEETHANJALI ADAPALA (Department of pharmacology).
RIPER, anantapur
Extrapolation of in vitro data to preclinical and.pptxARSHIKHANAM4
Extrapolation of in vitro data to preclinical.
the topic is included in m.pharmacy 1st sem syllabus. which is essential for the study and that include the details about how you deal with the preclinical data that will help to decide the NOEAL and LOEAL, the humane dose of the drug can be calculated and further formation is also done.
genetic variations and its role in health/ pharmacologysrivani mandaloju
Here is the reference for the above topic. I have collected the maximum information that i got from the internet. If any one need the complete information comment here.
Introduction to Screening Models of Anti-Atherosclerosis
Atherosclerosis, Screening models, In vitro models, In vivo models
Presented by
SHAIK FIRDOUS BANU
Department of Pharmacology
Introduction to Immunotherapeutics
Cell mediated & humoral immunity, Immunosuppressants, Immunostimulants
Presented by
G. Sai Swetha
Department of Pharmacology
Immunoassays have been widely used in many important areas of pharmaceutical analysis such as diagnosis of diseases, therapeutic drug monitoring, clinical pharmacokinetic and bioequivalence studies in drug discovery and pharmaceutical industries.
In this slide contains diabetics, classification, symptoms, complication, invivo and invitro screening models of anti diabetics.
Presented by: GEETHANJALI ADAPALA (Department of pharmacology).
RIPER, anantapur
Extrapolation of in vitro data to preclinical and.pptxARSHIKHANAM4
Extrapolation of in vitro data to preclinical.
the topic is included in m.pharmacy 1st sem syllabus. which is essential for the study and that include the details about how you deal with the preclinical data that will help to decide the NOEAL and LOEAL, the humane dose of the drug can be calculated and further formation is also done.
a short presentation about the types of treatments used in cancer therapy, including traditional chemotherapy, targeted therapy, immunotherapy and hormonal therapy. also a short talk about side effects and administration of the CTX drugs.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
2. IMMUNITY
Immunity is defined as the body's ability to protect itself from
an infectious disease. When you are immune to a disease,
your immune system can fight off infection from
it. Immunity is either innate or adaptive.
CLASSIFICATION
Barrier immunity
Innate immunity
Adaptive Immunity
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16. IMMUNOTHERAPY
Treatment or prevention of disease (such as an autoimmune
disorder, allergy, or cancer) that involves the stimulation,
enhancement, suppression, or desensitization of the immune
system.
17. Why immunotherapy…….?
Long lasting effects in cancer patients.
Had great success in fighting and preventing cancer
disease.
To reduce the side effects of chemotherapy.
Non toxic.
Stop, control or suppress process that permit cancer
growth.
Boost the immune system to destroy affecting Ag.
Prevents cancer cells from spreading.
Enhance the body ability to repair or replace damaged
normal cells.
19. IMMUNOSTIMULANTS
1. Non – specific immunotherapy
Use of cytokines and other chemicals that stimulate a
general immune response or removes the blockade of
immune activation against cancer cells.
Regulates the expression of several immunological
components including histocompatibility complex antigens,
immunosuppressive peptides, proto-oncogenes, cell
proliferation and apoptosis.
Administered directly into the body or by gene therapy.
20. Examples :-
IL-2 – induces T –cell immunity against cancer such as
metastatic melanoma and renal cell carcinoma.
IFN –α2a – hairy cell leukaemia
IFN-α2b - therapy of AIDS related kaposis sarcoma, hairy
cell leukaemia, follicular lymphoma, melanoma and
multiple myeloma.
21. 2. Monoclonal antibodies
Used for tagging the cancer cells for immune mediated killing
or altering the cell signalling pathways to inhibit proliferation or
inducing apoptosis.
Proteins and carbohydrate molecules present on surface of
cancer cells are potential targets for new antibody.
Receptors on the cancer cell surface are targets for antibodies
and binding leads to inhibition of normal signalling pathway
which could lead to cell survival and proliferation.
Examples:-
Trastuzumab – ERBB2
Rituximab - CD20
Bevacizumab- VEGF
Panitumab- EGFR
22. Ex :- cetuximab – inhibits epidermal growth factor
Antibodies also used for delivering the drugs to kill
cancer cells by conjugating the antibody to a radioactive
particles, immunotoxins or chemotherapeutic agents [ 90Y-
ibribumomab tiuxetan and 131 I- tositumomab ]
24. 3. Antibody directed enzyme prodrug therapy
Antibody is used as vector to transfer an enzyme that
converts prodrug to a cytotoxic agent
In this method, an Ab-enzyme conjugate is injected –
allowed to localize at the tumour cells depending on the
specificity of the Ab. Prodrug – cytotoxic drug.
Drawbacks
Immunogenicity of the enzyme
Short half life of the conjugates
Little anti-tumour activity
25.
26. 4. Immunotoxins
Source- plant derived or bacterial toxins
Targets specific antigen on the surface of cancer
cells.
These toxins inhibits elongation step of protein
synthesis.
Drawbacks - rapid clearance from blood stream and
immunogenicity.
Ex:- gelonin , ricin , abrin, pseudomonas exotoxin ,diptheria
toxin.
27.
28. IMMUNOMODULATORY
1. Adaptive cell therapy
Highly effective against metastatic melanoma.
In this, T – cell of patient having anti-tumour activity are
identified - isolated - grown exvivo - stimulated by tumour
APCs – infused back to the same patient.
Before infusion, high amounts of tumour infiltrating
lymphocytes is injected to host - to manipulate to increase
the effectiveness of the transferred cells.
Patient undergo lymphodepletion with either chemotherapy
or body irradiation - eliminates suppressive regulatory T-
cells, competitors of cytokines.
29.
30. 2. Cancer vaccines
Two types- preventive and therapeutic
Preventive vaccine
Prevents tumourgenesis caused by viral infections.
These are carcinogenic to viruses such as hepatitis B ,
Epstein bar virus , human papilloma virus , kaposis
sarcoma associated herpes virus.
Hep –B virus vaccine - hepatocellular carcinoma
Human papilloma virus vaccine - cervical cancer
31. Therapeutic vaccine
Used to increase an immune response to an existing cancer
cells.
Examples :-
1. Peptide / protein based vaccine
Derived from tumour cells as tumour cell specific
antigens for immunization.
ex:-vitespen – melanoma , locally renal cell
carcinoma.
GP-100 – melanoma
32. 2. Gene therapy based vaccine (viral vector vaccine)
The viral vectors are engineered to encode for specific
tumour antigens for the purpose of stimulating and
enhancing the immune responses against cancer cells.
Advantage - easy gene insertion , low cost , ability to
induce persistant immune response.
Ex:- prostvac – VF - prostate cancer
33.
34. Humanization antibody therapy
Antibody humanization methods are designed to produce a
molecule with minimal immunogenicity when applied to humans,
while retaining the specificity and affinity of the parental non-
human antibody.
Humanized antibodies are formed from non-human species
whose proteins sequence have been modified to increase
their similarity to antibodies which are produced naturally in
humans.
Non human antibodies are immumogenic in nature, hence
humanization is necessary.
35.
36. Technology to produce Antibody
Hybridoma technology using transgenic mouse.
Human antibody display.
Recombinant antibodies by cloning v- region genes.
Memory B-cell immortalization.
CDR- grafting.
37. Hybridoma technology
Production of hybrid cells – from spleen cells of
transgenic mice and human cells having antibody
Fusion - B –cells and myeloma cells to produce
hybridoma
Production of immortalized hybridoma [ cells that can
replicate in-vitro ]
Screening of hybridoma for desired specificity
Production of hybrid - hybridoma Ab by fusing 2 cells
2 Ab are formed in that one antibody contains 33%
mouse protein [ chimeric Ab ] and antibody contains 5-
10% mouse protein [ humanized antibody ]
38.
39. Memory B- cell immortalization
This technique involves isolation of human memory B
cells from peripheral blood mononuclear cells of
infected patients.
Immortalization of B cells using Epstein Barr virus in
the presence of a polyclonal B cell activator [ CpG
oligodeoxynucleotides ]
Transformed cells - capable of producing human clonal
antibody with desired antigen.
Culture - supernatants are screened for specific
antibodies.
Positive culture are cloned and fully humanized.